Prelude therapeutics announces publication of abstract for presentation at the european society of medical oncology (esmo) congress 2024

Prt3789, a novel, highly-selective smarca2 degrader in patients with advanced solid tumors with a smarca4 mutation oral session presentation: september 13, 2024, 4:00 pm cest (10:00 am est)

PRLD Ratings Summary

PRLD Quant Ranking